Parvovirus B19 transmitted by bone marrow

Heegaard, Erik D.; Petersen, Bodil Laub

doi:10.1046/j.1365-2141.2000.02407.x

Cited by 46 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, a mechanism analogous to that of varicella might be possible, in which an age-related diminished level of antibodies or cellmediated immunity can lead to low-grade reactivation or reinfection, with detectable levels of B19 DNA possibly found exclusively in the BM without accompanying overt clinical symptoms. It has been proposed that B19 screening of blood components destined for children with malignancies be implemented (4), and this may well include testing of BM donors prior to BM transplantation, given the present results and the discovery of symptomatic B19 infection transmitted by BM (12).…”

Section: B19 Is a Ubiquitous Infectious Agent And Is Transmitted By Tmentioning

confidence: 99%

Prevalence of Parvovirus B19 and Parvovirus V9 DNA and Antibodies in Paired Bone Marrow and Serum Samples from Healthy Individuals

Heegaard

Petersen²,

Heilmann

et al. 2002

J Clin Microbiol

Self Cite

View full text Add to dashboard Cite

Parvovirus B19 (hereafter referred to as B19) exhibits a marked tropism to human bone marrow (BM), and infection may lead to erythema infectiosum, arthropathy, hydrops fetalis, and various hematologic disorders. Recently, a distinct parvovirus isolate termed V9 with an unknown clinical spectrum was discovered. In contrast to the many studies of B19 serology and viremia, valid information on the frequency of B19 or V9 DNA in the BM of healthy individuals is limited. To develop a reference value, paired BM and serum samples from healthy subjects were tested for the presence of B19 and V9 DNA and specific antibodies. Immunoglobulin M (IgM) was not found in any of the serum samples. The prevalence of IgG showed a gradual and steady increase from 37% in children aged 1 to 5 years to 87% in people aged >50 years. When 190 well-characterized subjects were examined, B19 DNA was detected in the BM of 4 individuals (2.1%; 95% confidence interval, 0.58 to 5.3%) while none of the paired serum samples showed evidence of circulating viral DNA. V9 DNA was not found in any of the BM or serum samples. The finding of B19 DNA probably indicated a primary infection in one 7-year-old individual and reinfection or reactivation of persistent infection in the remaining three persons, aged 47 to 58 years. Serving as a benchmark for future studies, these findings are useful when interpreting epidemiologic data, performing BM transplantation, or considering clinical implications of parvovirus infection.Human parvovirus B19 (hereafter referred to as B19) is a member of the genus Erythrovirus of the family Parvoviridae (18). B19 exhibits a marked tropism to human bone marrow (BM) and replicates only in erythroid progenitor cells (3). Infection may lead to erythema infectiosum, arthropathy, hydrops fetalis, and various hematologic disorders, including aplastic crisis, chronic anemia, and idiopathic thrombocytopenic purpura (3). Diagnosis of B19 relies on serology and the detection of viral DNA by PCR or dot blot analysis. A possible emerging parvovirus isolate termed V9 with an unknown clinical spectrum and markedly different from B19 (Ͼ11% nucleotide disparity) was recently discovered (19). Sequencing, combined with PCR studies, has since demonstrated the need for specific and differentiated techniques when examining samples for possible B19 or V9 viremia (11). Conversely, cloning and production of the V9 capsid proteins and subsequent enzymelinked immunosorbent assay studies have revealed a 100% serologic cross-reactivity between the B19 and V9 isolates (13).The prevalence of immunoglobulin G (IgG) antibodies directed against B19 ranges from 15 to 60% in children 6 to 19 years old: and from 30 to 60% in adults and is more than 85% in the geriatric population (1,7,22). The frequency of B19 viremia in voluntary blood donors has been estimated at rates of 1:167 to 1:35,000 (11,14,17,(22)(23)(24). As opposed to the many studies on B19 serology and viremia, information on the presence of B19 DNA in the BM of healthy individuals is limited. Thou...

show abstract

Section: B19 Is a Ubiquitous Infectious Agent And Is Transmitted By Tmentioning

confidence: 99%

Prevalence of Parvovirus B19 and Parvovirus V9 DNA and Antibodies in Paired Bone Marrow and Serum Samples from Healthy Individuals

Heegaard

Petersen²,

Heilmann

et al. 2002

J Clin Microbiol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Transmission of infection usually occurs by inhalation of virus in aerosol droplets (16). Infection also can be transmitted vertically from mother to fetus (17) and less commonly through transfusion of blood products (18), bone marrow transplants (19), and solid-organ transplants (20,21).…”

Section: Epidemiologymentioning

confidence: 99%

Parvovirus B19 and the Kidney

Waldman¹,

Kopp²

2007

Clinical Journal of the American Society of Nephrology

112

105

View full text Add to dashboard Cite

“…Transmission of parvovirus B19 by bone marrow transplantation has been described. 17 Parvovirus can cause pancytopenia, but the overall risk of parvovirus B19 infection and disease transmitted by HCT is very limited and routine testing is not recommended.…”

Section: Virusesmentioning

confidence: 99%

Transmission of donor illness by stem cell transplantation: should screening be different in older donors?

Niederwieser¹,

Gentilini²,

Hegenbart³

et al. 2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:With increasing donor age, the potential of transmitting diseases from donor to recipient reaches new dimensions. Potentially transmittable diseases from donors include infections, congenital disorders, and acquired illnesses like autoimmune diseases or malignancies of hematological or nonhematological origin. While established nonmalignant or malignant diseases might be easy to discover, earlystage hematological diseases like CML, light-chain multiple myelomas, aleukemic leukemias, occult myelodysplastic syndromes and other malignant and nonmalignant diseases might not be detectable by routine screening but only by invasive, new and/or expensive diagnostic tests. In the following article, we propose recommendations for donor work-up, taking into consideration the age of the donors. In contrast to blood transfusions, stem cells from donors with abnormal findings might still be acceptable for HCT, when no other options are available and life expectancy is limited. This issue is discussed in detail in relation to the available donor and stem cell source. Finally, the recommendations presented here aim at harmonized worldwide work-up for donors to insure high standard quality.

show abstract

Parvovirus B19 transmitted by bone marrow

Cited by 46 publications

References 15 publications

Prevalence of Parvovirus B19 and Parvovirus V9 DNA and Antibodies in Paired Bone Marrow and Serum Samples from Healthy Individuals

Prevalence of Parvovirus B19 and Parvovirus V9 DNA and Antibodies in Paired Bone Marrow and Serum Samples from Healthy Individuals

Parvovirus B19 and the Kidney

Transmission of donor illness by stem cell transplantation: should screening be different in older donors?

Contact Info

Product

Resources

About